AC Immune S.A.
General ticker "ACIU" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $249.6M (TTM average)
AC Immune S.A. follows the US Stock Market performance with the rate: 56.4%.
Estimated limits based on current volatility of 3.9%: low 3.01$, high 3.25$
Factors to consider:
- Earnings expected soon, date: 2026-04-29 bmo
- Total employees count: 67 as of 2016
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.36$, 5.31$]
- 2026-12-31 to 2027-12-31 estimated range: [2.35$, 5.24$]
Financial Metrics affecting the ACIU estimates:
- Positive: with PPE of -3.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -26.70 <= 0.07
- Positive: Investing cash flow per share per price, % of 24.50 > -0.65
- Positive: Interest expense per share per price, % of 0.07 <= 0.73
- Positive: 19.49 < Shareholder equity ratio, % of 29.10 <= 42.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ACIU quotes
Long-term ACIU plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | CHF14.80MM | CHF27.31MM | CHF3.57MM |
| Operating Expenses | CHF68.42MM | CHF79.69MM | CHF72.44MM |
| Operating Income | CHF-53.62MM | CHF-52.38MM | CHF-68.86MM |
| Non-Operating Income | CHF-0.60MM | CHF1.47MM | CHF-1.58MM |
| Interest Expense | CHF0.18MM | CHF0.13MM | CHF0.18MM |
| R&D Expense | CHF54.61MM | CHF62.57MM | CHF53.90MM |
| Income(Loss) | CHF-54.22MM | CHF-50.91MM | CHF-70.45MM |
| Taxes | CHF0.01MM | CHF0.00MM | CHF0.00MM |
| Profit(Loss)* | CHF-54.23MM | CHF-50.92MM | CHF-67.28MM |
| Stockholders Equity | CHF160.64MM | CHF112.27MM | CHF44.93MM |
| Assets | CHF182.81MM | CHF230.91MM | CHF154.43MM |
| Operating Cash Flow | CHF-60.41MM | CHF65.84MM | CHF-66.15MM |
| Capital expenditure | CHF0.80MM | CHF0.58MM | CHF0.86MM |
| Investing Cash Flow | CHF65.64MM | CHF-105.29MM | CHF60.69MM |
| Financing Cash Flow | CHF43.25MM | CHF-1.12MM | CHF-0.97MM |
| Earnings Per Share** | CHF-0.64 | CHF-0.51 | CHF-0.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.